Preventing Atrial Fibrillation Related Stroke with Anticoagulants: Selecting Appropriate Therapy for Individual Patients

Title:

Preventing Atrial Fibrillation Related Stroke with Anticoagulants: Selecting Appropriate Therapy for Individual Patients

Topic: Cardiology
Relevant Terms: Anticoagulation; Stroke; Atrial Fibrillation; Bleeding Risk
Primary Audience: Cardiologists, Hospitalists, MDs, NPs, PCPS, Physician Assistants and Pharmacists, RNs
Launch Date: 01-Feb-13
Credits: AMA PRA Category 1 Credit
1 ACPE contact hour
1.16 ANCC contact hours
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Selecting Anticoagulant Therapy for Patients with Atrial Fibrillation

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe benefits of oral anticoagulants for stroke prevention in atrial fibrillation 
  2. Identify the population of patients who would be at risk of stroke with atrial fibrillation 
  3. Compare current and new oral anticoagulants with regards to safety, efficacy, pharmacology, cost and convenience 
  4. Compare the benefits and risks of oral anticoagulant therapy for reducing the risk of stroke in atrial fibrillation patients 
  5. Utilize available decision making tools to stratify the risks and benefits of anticoagulation therapy in patients with atrial fibrillation 

    Faculty

    Elaine Hylek, MD, MPH
    Program Course Director
    Professor of Medicine
    Boston University School of Medicine
    Director, Thrombosis Clinic and Anticoagulation Service    
    Boston Medical Center
    Boston, Massachusetts 
    Scott Kaatz DO, MSc, FACP
    Chief Quality Officer
    Hurley Medical Center
    One Hurley Plaza
    Flint, Michigan
    DISCLOSURE POLICY STATEMENT
     
    Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 
     
    Faculty Disclosures
     
    Dr. Elaine Hylek is a consultant for Bayer, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Daiichi-Sankyo, and Johnson and Johnson. She also receives grant/research funding from Bristol Myers Squibb/Pfizer and Johnson and Johnson. She additionally has spoken at symposiums for Bayer, Boehringer Ingelheim and Bristol Myers Squibb/Pfizer.
     
    Dr. Kaatz receives grant/research support from Bristol Myers Squibb, Boehringer Ingelheim, Bayer/Jansen/Johnson and Johnson, Eisai, Iverson Genetics Diagnostics/Medicare, NIH, Canadian Institute of Health Research and Blue Cross and Blue shield of Michigan. He is on the speakers bureau of Bayer/Jansen/ Johnson and Johnson, Boehringer Ingelheim and GlaxoSmithKline. He is also a consultant for Boehringer Ingelheim, Bristol Myers Squibb, Squibb/Pfizer, and Daiichi Sankyo.
     
    *Unlabeled/investigational uses of commercial products are not discussed in this activity.
     
    Planning Committee Disclosures
     
    Ms. Patti-Ann Collins, Boston University's Continuing Medical Education department's Lead Nurse Planner, has nothing to disclose with regards to commercial support.
     
    Dr. Christina Cove, Boston University's Continuing Medical Education department's independent CME content reviewer, has nothing to disclose with regards to commercial support.
     
    Ms. Janet Delaney, Anticoagulation Forum's Nursing Course Advisor, has nothing to disclose with regards to commercial support.
     
    Ms. Elizabeth Goldstein, Executive Director of Anticoagulation Forum, has nothing to disclose with regards to commercial support.
     
     
    DISCLOSURE ATTESTATION
     
    Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices occurs.
     
    DISCLAIMER
     
    THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
     
    Non-Endorsement of Products
    Continuing Nursing Education Provider Unit, Boston University School of Medicine's provider status refers only to continuing nursing education activities and does not imply that there is real or implied endorsement by Continuing Nursing Education Provider Unit, Boston University School of Medicine or ANCC of any product, service, or company referred to in this activity nor of any company subsidizing costs related to the activity.
     
     
    CREDIT DESIGNATION
     
    Boston University School of Medicine designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
     
    ACCREDITATION STATEMENT
     
    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and Anticoagulation Forum. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
     
    This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and co-provided by Anticoagulation Forum.
     
    Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
     
    CNE Contact Hours: 1.16, all of which are pharmacology credit worthy.
     
    Nurses will receive contact hours for those sessions attended, after completion of an evaluation and claim for credit form.

     
    Continuing Pharmacy Education Credits
    The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Attendance and completion of program evaluations at the conclusion of the program are required for a statement of credit. This knowledge-based activity is approved for 1.0 Contact Hours (0.1 CEUs). UAN: 0060-9999-13-011-H01-P. Expiration date: January 31st, 2014
     

    HOW TO RECEIVE CREDIT

    By reviewing the course content and successfully completing the post-test and
    evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™, nurses are entitled to receive 1.16 CNE contact hours, all of which are pharmacology credit worthy, and pharmacists will receive 1.0 Contact Hours(0.1 CEUs). Statement of credit will be available to print from your user history page.
     
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians, nurses and pharmacists who successfully complete the post-test and evaluation will resepectively receive CME, CNE or ACPE credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    *Note to Pharmacists: to receive CE credits you must submit your NABP ID number. You will be prompted to submit your ID number at the end of the activity, after completing the posttest, when claiming your credits. This is mandatory and the CE credits are not valid unless an NABP ID is submitted.
    If you do not have an ID number you can obtain one at the following link:
    http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service/

     
    COURSE VIEWING REQUIREMENTS

    Google Chrome for Windows, Mac, or Linux
    Internet Explorer 7.0+ for Windows
    Mozilla 1.4+ for Windows, Mac, or Linux
    Firefox 3.5+ for Windows, Mac, or Linux
    Safari 4.0+ for Mac
     
    Release Date: February 1, 2013
    Expiration Date: January 31, 2014

    Program Code: E.ANTICOAGAF12
     
    For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
    To view Boston University's Privacy Policy, please see http://www.bumc.bu.edu/cme/policies/.
    RealCME Privacy Policy: http://www.realcme.com/cms/privacypolicy
     

    COMMERCIAL SUPPORT

    This continuing medical education activity is sponsored by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Bristol-Myers Squibb and Pfizer Inc.